---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-384360"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2026-09-08T11:02:13+00:00"
generated_at: "2026-09-08T11:05:16.369430+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa earns $50M milestone as Novartis starts Phase 2 Sjögren's study of MRT-6160

## Summary
- Novartis initiated Phase 2a/b double-blind, placebo-controlled trial of VAV1 degrader MRT-6160 (DDY391) in Sjögren's disease; first patient visit triggers $50M payment to Monte Rosa.
- Study tests up to 52 weeks of treatment; identifier NCT07737743; dose selection for Phase 3.
- Monte Rosa eligible for up to $2.1B in development, regulatory, sales milestones from Novartis agreement.
- Phase 1 data showed >90% VAV1 degradation in T cells with no serious adverse effects; additional Phase 2 studies expected.
- Novartis funds Phase 2; Monte Rosa co-funds Phase 3 and shares 30% of U.S. profits/losses, plus ex-U.S. royalties.

## SEC filing metadata
- accession: 0001193125-26-384360
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2026-09-08T11:02:13+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/0001193125-26-384360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/glue-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-384360
- JSON: https://secwatch.observer/filing/0001193125-26-384360.json
- Plain text: https://secwatch.observer/filing/0001193125-26-384360.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.